Lawyers USA has ceased publication. If you have purchased a research pass or still have additional time on your current Digital Subscription, you may access locked stories by logging in.
Merck settles Vytorin shareholder class action suit
Merck will pay $5.1 million in attorney fees and institute corporate reforms under the terms of a settlement of a shareholder class action concerning the alleged suppression of negative clinical test results for the blockbuster anti-cholesterol drug Vytorin.